BE2014C008I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C008I2
BE2014C008I2 BE2014C008C BE2014C008C BE2014C008I2 BE 2014C008 I2 BE2014C008 I2 BE 2014C008I2 BE 2014C008 C BE2014C008 C BE 2014C008C BE 2014C008 C BE2014C008 C BE 2014C008C BE 2014C008 I2 BE2014C008 I2 BE 2014C008I2
Authority
BE
Belgium
Application number
BE2014C008C
Other languages
French (fr)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23078354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2002/010773 external-priority patent/WO2002080897A1/en
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BE2014C008I2 publication Critical patent/BE2014C008I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2014C008C 2001-04-05 2014-02-13 BE2014C008I2 (US08124317-20120228-C00026.png)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28168501P 2001-04-05 2001-04-05
GBGB0123571.2A GB0123571D0 (en) 2001-04-05 2001-10-02 Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
PCT/US2002/010773 WO2002080897A1 (en) 2001-04-05 2002-04-04 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
BE2014C008I2 true BE2014C008I2 (US08124317-20120228-C00026.png) 2021-02-04

Family

ID=23078354

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C008C BE2014C008I2 (US08124317-20120228-C00026.png) 2001-04-05 2014-02-13

Country Status (6)

Country Link
US (2) US6794410B2 (US08124317-20120228-C00026.png)
BE (1) BE2014C008I2 (US08124317-20120228-C00026.png)
CY (1) CY1110446T1 (US08124317-20120228-C00026.png)
EC (1) ECSP024244A (US08124317-20120228-C00026.png)
GB (1) GB0123571D0 (US08124317-20120228-C00026.png)
HN (1) HN2002000110A (US08124317-20120228-C00026.png)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR245601A0 (en) 2001-01-10 2001-02-01 Silverbrook Research Pty Ltd An apparatus (WSM09)
JP2010513518A (ja) * 2006-12-19 2010-04-30 メリマック ファーマシューティカルズ インコーポレーティッド 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
EP2277515A1 (en) 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
CN104739821B (zh) * 2009-09-18 2018-04-06 赛诺菲 稳定性提高的(z)‑2‑氰基‑3‑羟基‑丁‑2‑烯酸‑(4’‑三氟甲基苯基)‑酰胺片剂制剂
EP2314291A1 (en) 2009-10-22 2011-04-27 Sanofi-Aventis Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis
KR20120089295A (ko) 2009-10-22 2012-08-09 사노피-아벤티스 유.에스. 엘엘씨 다발성 경화증을 치료하기 위한 테리플루노마이드 및 글라티라머 아세테이트의 병용 용도
AR081764A1 (es) 2010-05-26 2012-10-17 Sanofi Aventis Us Llc Uso de teriflunomida para mantener el nivel de fatiga de un paciente que tiene esclerosis multiple, articulo de fabricacion y envase
AR081220A1 (es) 2010-05-26 2012-07-04 Sanofi Aventis Us Llc Uso de teriflunomida para el tratamiento de la atrofia cerebral
AR082436A1 (es) 2010-08-02 2012-12-05 Sanofi Aventis Us Llc Uso de teriflunomida para tratar la esclerosis multiple
DK2608782T3 (en) * 2010-08-24 2016-09-05 Algiax Pharmaceuticals Gmbh New use of leflunomide malononitrilamider
WO2012061062A1 (en) * 2010-10-25 2012-05-10 Sanofi-Aventis U.S. Llc Use of teriflunomide for improving motor function
WO2012061060A1 (en) 2010-10-25 2012-05-10 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating brain atrophy
US20130217737A1 (en) * 2010-10-29 2013-08-22 Al-Giax Pharmaceuticals Gmbh Use of Malononitrilamides in Neuropathic Pain
AR085305A1 (es) 2011-02-24 2013-09-18 Sanofi Aventis Us Llc Uso de la teriflunomida para el tratamiento del deterioro cognitivo
WO2012162339A1 (en) 2011-05-24 2012-11-29 Sanofi-Aventis U.S. Llc Use of teriflunomide for reducing occurrence of relapses requiring healthcare resources
RU2471482C1 (ru) * 2011-10-27 2013-01-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
EP2762135A1 (en) 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) * 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US4284784A (en) * 1980-05-22 1981-08-18 Merck & Co., Inc. Process for the preparation of 4-methyl thiazole
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US4965278A (en) * 1989-04-21 1990-10-23 Warner-Lambert Company 7-(substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro[4,5]decanes as diuretics antiiflammatory, and cerebrovascular agents
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
IT1254519B (it) 1992-03-16 1995-09-25 Chiesi Farma Spa Associazioni di composti ad attivita' antivirale
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DE19534649A1 (de) 1995-09-19 1997-03-20 Hoechst Ag 2-Cyano-3-mercaptocrotonsäureamide
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
US5856330A (en) 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US6011051A (en) 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US5981536A (en) 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
DE59801792D1 (de) 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
DE19857009A1 (de) 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
ES2237553T3 (es) * 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.

Also Published As

Publication number Publication date
US20030223960A1 (en) 2003-12-04
ECSP024244A (es) 2002-08-01
CY1110446T1 (el) 2015-04-29
GB0123571D0 (en) 2001-11-21
US6794410B2 (en) 2004-09-21
HN2002000110A (es) 2002-07-04
US20020177623A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
BE2022C531I2 (US08124317-20120228-C00026.png)
BE2022C502I2 (US08124317-20120228-C00026.png)
BE2022C547I2 (US08124317-20120228-C00026.png)
BE2017C057I2 (US08124317-20120228-C00026.png)
BE2017C051I2 (US08124317-20120228-C00026.png)
BE2017C032I2 (US08124317-20120228-C00026.png)
BE2016C051I2 (US08124317-20120228-C00026.png)
BE2015C046I2 (US08124317-20120228-C00026.png)
BE2014C052I2 (US08124317-20120228-C00026.png)
BE2014C036I2 (US08124317-20120228-C00026.png)
BE2014C026I2 (US08124317-20120228-C00026.png)
BE2014C004I2 (US08124317-20120228-C00026.png)
BE2014C006I2 (US08124317-20120228-C00026.png)
BE2017C050I2 (US08124317-20120228-C00026.png)
BE2011C034I2 (US08124317-20120228-C00026.png)
BE2007C047I2 (US08124317-20120228-C00026.png)
AU2002307149A8 (US08124317-20120228-C00026.png)
BRPI0209186B1 (US08124317-20120228-C00026.png)
BE2014C008I2 (US08124317-20120228-C00026.png)
BRPI0204884B1 (US08124317-20120228-C00026.png)
CH1379220H1 (US08124317-20120228-C00026.png)
BE2016C021I2 (US08124317-20120228-C00026.png)
BE2017C059I2 (US08124317-20120228-C00026.png)
BRPI0101486B8 (US08124317-20120228-C00026.png)
BE2012C051I2 (US08124317-20120228-C00026.png)